Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial-Reference-Cited by-同舟云学术

Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial

Published:2024-05 Issue:5 Volume:25 Page:626-635
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Burris Howard A,Okusaka Takuji,Vogel Arndt,Lee Myung Ah,Takahashi Hidenori,Breder Valeriy,Blanc Jean-Frédéric,Li Junhe,Bachini Melinda,Żotkiewicz Magdalena,Abraham Jayne,Patel Nikunj,Wang Julie,Ali Muzammil,Rokutanda Nana,Cohen Gordon,Oh Do-Youn

Funder

AstraZeneca Pharmaceuticals LP

Publisher

Elsevier BV

Reference28 articles.

1. Biliary tract cancer;Valle;Lancet,2021

2. Immunotherapy in advanced biliary tract cancers;Boilève;Cancers (Basel),2021

3. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer;Valle;N Engl J Med,2010

4. Gemcitabine plus cisplatin for advanced biliary tract cancer: a systematic review;Park;Cancer Res Treat,2015

5. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer;Oh;NEJM Evid,2022

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HSF1 is a prognostic determinant and therapeutic target in intrahepatic cholangiocarcinoma;Journal of Experimental & Clinical Cancer Research;2024-09-06

2. Delayed-Onset Immune-Related Colitis Following Pancreaticoduodenectomy in Patients With Gastric Cancer and Pancreatic Invasion Treated With Immune Checkpoint Inhibitors;Cureus;2024-09-02

3. Durvalumab plus chemotherapy enhances 3-year survival in advanced biliary tract cancer;Medicom Conference Report ESMO GI 2024;2024-08-21

4. Strategies for treating the cold tumors of cholangiocarcinoma: core concepts and future directions;Clinical and Experimental Medicine;2024-08-14

5. Immunotherapy in biliary tract cancer: are we finally on the right path?;The Lancet Gastroenterology & Hepatology;2024-08